Merck's shares surged after Phase 3 INTerpath-001 data showed intismeran plus Keytruda met recurrence-free and distant-metastasis-free survival endpoints in resected melanoma, reinforcing confidence in Merck's immuno-oncology franchise extension. The move is largely catalyst-driven rather than tied to earnings or guidance changes, with sector-wide spillover evident via Moderna's sharp rally. Near-term focus shifts to full dataset details, regulatory pathway, and pending overall-survival readout.
AI Insight · NCSKMRK2USD/USDTAI Insight
▲ Bullish
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Merck (MRK) rose 12.60% to $152.20 on August 19, 2026 after positive Phase 3 intismeran-Keytruda melanoma data. Read its momentum risk and key technical levels.